PM
CRSP icon

Prosight Management’s CRISPR Therapeutics CRSP Stock Holding History

Prosight Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-34,000
Closed -$2.13M – 27
2022
Q1 		$2.13M Buy
34,000
+16,636
+96% +$1.04M 1.38% 21
2021
Q4 		$1.32M Buy
+17,364
New +$1.52M 0.79% 27

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Prosight Management's CRSP Position: Q2 2022 in Review

Prosight Management sold out of CRISPR Therapeutics (CRSP) in Q2 2022, closing a stake of 34,000 shares — an estimated $2.13M sold.

Prosight Management first reported a position in CRSP in Q4 2021 and held it in 2 quarters. The position peaked at $2.13M in Q1 2022. 435 funds tracked by Wall St. Rank hold CRSP as of Q2 2022.

  • Prosight Management reported no remaining CRISPR Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prosight Management sold 34,000 CRISPR Therapeutics shares in Q2 2022, an estimated $2.13M.
  • Prosight Management first reported a position in CRISPR Therapeutics in Q4 2021 and held it in 2 quarters.
  • Prosight Management's CRISPR Therapeutics position peaked at $2.13M in Q1 2022.
  • 435 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2022.

Based on Prosight Management's 13F filing for Q2 2022, filed 12 Aug 2022.